Loading clinical trials...
Loading clinical trials...
Combined Approach to GBM-resection by 5-ALA and Intraoperative MRI
In the treatment of glioblastoma (GBM) neurosurgical resection of the tumor is usually considered a a first step of effective therapy. Radical resection of the tumor is highly beneficial to the patient as measured in progression-free survival and overall survival. At the same time eloquent areas of the brain have to remain intact to preserve quality of life. Both 5-ALA fluorescence and intraoperative MRI are used for intraoperative marking of tumor tissue and thereby to improve precision of GBM-Resection. We now study whether the combination of 5-ALA fluorescence and intraoperative MRI increases the number of sites where tumor tissue can be detected. \- Trial with surgical intervention
Precision of GBM-Resection Intraoperative marking of tumor tissue Combination of 5-ALA fluorescence and intraoperative MRI
Age
20 - 70 years
Sex
ALL
Healthy Volunteers
No
UniversitätsSpital Zürich
Zurich, Switzerland
Start Date
August 1, 2009
Primary Completion Date
December 1, 2011
Completion Date
December 1, 2011
Last Updated
October 22, 2010
40
ESTIMATED participants
diagnostic 5-ALA and MRI for tumor resection
PROCEDURE
Lead Sponsor
University of Zurich
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06860594